Anti-Fibrinolytic Drugs - Italy

Italy

Italy is projected to experience significant growth in the Anti-Fibrinolytic Drugs market.
By 2024, the revenue in this market is expected to reach €254.40m.
Looking ahead, the market is anticipated to display an annual growth rate (CAGR 2024-2029) of 4.28%, resulting in a market volume of €313.70m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, reaching €9,141.00m in 2024.
Italy's growing demand for anti-fibrinolytic drugs is driven by an aging population and increasing prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Italy has seen a steady growth in recent years.

Customer preferences: Anti-Fibrinolytic Drugs are used to prevent excessive bleeding during surgeries and are prescribed to patients with bleeding disorders. The Italian market for these drugs is predominantly driven by hospitals and surgical centers. The demand for these drugs is high as they are considered an essential component of surgical procedures.

Trends in the market: The Italian market for Anti-Fibrinolytic Drugs is expected to grow at a steady rate due to the increasing number of surgeries performed in the country. As the population continues to age, the number of surgeries is expected to increase, which will further drive the demand for these drugs. Moreover, the increasing prevalence of bleeding disorders in the country is also expected to contribute to the growth of the market.

Local special circumstances: Italy has a well-established healthcare system that provides universal coverage to its citizens. The country has a high number of hospitals and surgical centers, which contributes to the demand for Anti-Fibrinolytic Drugs. Additionally, the Italian government has implemented policies and regulations to ensure the quality and safety of these drugs. This has led to an increase in the confidence of healthcare professionals and patients in these drugs, which has further contributed to the growth of the market.

Underlying macroeconomic factors: The Italian economy has been experiencing slow growth in recent years, which has led to a decrease in healthcare spending. However, despite this, the demand for Anti-Fibrinolytic Drugs has remained strong due to the essential nature of these drugs in surgical procedures. Moreover, the Italian government has implemented measures to control healthcare costs, which has led to an increase in the use of generic versions of these drugs. This has further contributed to the growth of the market as the availability of cheaper alternatives has made these drugs more accessible to patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.